EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access

SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis

Arif Saleem, Haris Shinwari, Muhammad Usman, Kamran Adil, Asfandyar Khan, Humam Shah, Iftikhar Ahmad iD

Diabetology International · 2026-10 · 17 (4)

DOI: 10.1007/s13340-026-00934-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetology International, online erschienen am 05.10.2026. Verfasst von Arif Saleem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Hypertension Hospital, Khyber Medical University, Dera Ismail Khan, Pakistan. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study evaluates the efficacy of combination therapy with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i) versus DPP-4i monotherapy in patients with type 2 diabetes mellitus (T2DM) who remained inadequately controlled on metformin.

Methods

Randomized controlled trials (RCTs) investigating adults with T2DM inadequately controlled on metformin, comparing the combination of SGLT-2i plus DPP-4i versus DPP-4i add-on therapy alone were systematically reviewed. PubMed/Medline, Google Scholar, Embase, and CENTRAL were searched without language restriction. The primary outcomes were change in HbA1c and in fasting plasma glucose (FPG) from baseline, proportion of patients attainting HbA1c < 7.0%, and body weight reduction. Secondary outcomes included hypoglycemia risk, genital infection, urinary tract infection (UTI), and overall and serious adverse events (AEs). Pooled analyses were carried out using the random-effects model.

Results

Eleven RCTs (3662 patients) were pooled. Compared with DPP-4i alone, adding a combination of SGLT-2i plus DPP-4i after metformin significantly reduced HbA1c (MD: - 0.47%; 95% CI (- 0.54, - 0.41); GRADE: high), increased the proportion of patients attaining HbA1c < 7.0% (RR: 1.71; 95% CI (1.52, 1.93); GRADE: moderate), reduced FPG (MD: - 15.75 mg/dL; 95% CI (- 21.56, - 9.93); GRADE: moderate), increased genital infection (RR: 2.83 (95% CI 1.02, 7.87; GRADE = moderate), and produced greater body weight reduction (MD: - 1.46 kg; 95% CI (- 1.93, - 0.99); GRADE: moderate). The risk of UTI and overall and serious AEs were insignificantly different between arms.

Conclusion

The combinatorial therapy using SGLT-2i and DPP-4i produces a significantly better glycemic control and body weight compared with DPP-4i therapy alone, without increasing the overall safety burden. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13340-026-00934-1.

Schlagwörter

Stichwörter der Autor:innen

Body weightFasting plasma glucoseGenital infectionHypoglycemiaUrinary tract infection

Autor:innen und Institutionen

  • Diabetes and Hypertension Hospital, Khyber Medical University, Dera Ismail Khan, Pakistan.
  • Khyber Medical College, Peshawar, Pakistan.
  • Institute of Radiotherapy and Nuclear Medicine, Peshawar, Pakistan.

ORCID-Profile: Iftikhar Ahmad

Zitieren

APA

Saleem, A., Shinwari, H., Usman, M., Adil, K., Khan, A., Shah, H., & Ahmad, I. (2026). SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis. Diabetology International, 17(4). https://doi.org/10.1007/s13340-026-00934-1

Vancouver

Saleem A, Shinwari H, Usman M, Adil K, Khan A, Shah H, et al. SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis. Diabetology International. 2026;17(4). doi:10.1007/s13340-026-00934-1

BibTeX
@article{Saleem2026,
  author = {Saleem, Arif and Shinwari, Haris and Usman, Muhammad and Adil, Kamran and Khan, Asfandyar and Shah, Humam and Ahmad, Iftikhar},
  title = {SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis},
  journal = {Diabetology International},
  year = {2026},
  volume = {17},
  number = {4},
  doi = {10.1007/s13340-026-00934-1}
}
Kostenlos starten →